Last reviewed · How we verify

Supergene, LLC — Portfolio Competitive Intelligence Brief

Supergene, LLC pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
non-immunogenic staphylokinase non-immunogenic staphylokinase phase 3 Fibrinolytic agent Plasminogen Cardiovascular
Non-immunogenic recombinant staphylokinase Non-immunogenic recombinant staphylokinase phase 3 Fibrinolytic agent / Plasminogen activator Plasminogen Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Capital Medical University · 1 shared drug class
  2. Kedrion S.p.A. · 1 shared drug class
  3. University of North Carolina, Chapel Hill · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Supergene, LLC:

Cite this brief

Drug Landscape (2026). Supergene, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/supergene-llc. Accessed 2026-06-10.

Related